Résultats pour
DELPHI GENETICS
Belgique
Traditionally clone selection was based on the disruption of a genetic marker (e.g. blue and white screening based on the disruption of the LacZ gene), plasmid retention was based on antibiotic resistance genes. The development of vectors employing selection modules circumvents these issues and permits growth of bacteria harbouring insert-bearing plasmids only. Typically, the vectors used in these systems express a gene product that is lethal to certain bacterial hosts. The lethal gene is inactivated by insertion of a segment of foreign DNA and therefore, toxicity is relieved. The most efficient technical solution remains the killing of bacteria harbouring an insertless vector, or the selection of bacteria harbouring the recombinant vector, the so-called positive selection. The ccdB technology developed by Delphi Genetics has proven to be a successful approach for constructing positive selection vectors
Demander un devisDELPHI GENETICS
Belgique
Because the stabilization relies on the presence of only two genetic elements, one on the plasmid the other in the expression strain, the stabilization technology is readily adaptable into any existing E.Coli based expression platform. Delphi Genetics can customize any vectors and strains by adding the stabilization cassette into the vector and the selection gene into the chromosome of the chosen expression strain. Furthermore Delphi Genetics has developed a comprehensive licensing policy for those who would wish to integrate the stabilization system into an existing platform.
Demander un devisDELPHI GENETICS
Belgique
In order to maximize protein expression, the Staby® system was combined to the proven T7 polymerase technology for the over-expression of recombinant proteins: the gene of interest is under the control of the T7 promoter. This combination is called StabyExpress®. The pStaby1 plasmid contains the gene encoding the antidote protein (ccdA) which counteracts the action of the ccdB protein. The SE1 strain, in which the ccdB selection gene is inserted in the chromosome in order to stabilize the pStaby1 plasmid has been engineered by Delphi Genetics as a dedicated bacterial strain for protein expression and is derived from BL21(DE3). Consequently, IPTG has to be used to induce protein expression, an alternative strategy being the use of an auto-inducible medium (such as Delphi Genetics' Staby®Switch medium). Staby®Express ensures that only plasmid-bearing clones can grow whereas every clone losing the plasmid will inevitably die.
Demander un devisDELPHI GENETICS
Belgique
Modern DNA engineering requires efficient and robust molecular tools. The Staby® Operating System, developed by Delphi Genetics is an original set of bacterial strains and vectors integrating unique patented technologies. The use of these products and technologies allows researchers to reach their goal faster and more efficiently. These technologies can be used in a project of any scale (from laboratory scale to industrial processes). The Staby® Operating system is very flexible and its elements can be integrated into your favorite tools, allowing you to add the power of the Delphi-Genetics technologies into your own platform.
Demander un devisDELPHI GENETICS
Belgique
We are continuously improving and developing our Staby® technology to provide new adaptation proposing the best solution to our Customer. The Staby® technology has been adaptated in different fields and can be proposed on a tailor made solution basis or on a service basis. The Staby® technology applications actually available are the following. Feel free to contact us for other request
Demander un devisDELPHI GENETICS
Belgique
Delphi Genetics offers the benefits of its proprietary Staby® technology through partnering opportunities. We intend to build high-value strategic collaborations for exploring the benefits of the Staby® technology in various DNA & Protein bioproduction settings. Partnering is a key component of our service delivery strategy. Delphi Genetics is open to consider any collaborative projects at all stages of development from R&D to the commercialization of your bioproduct. We seek collaborative partnerships with Biotech & Pharma companies that could enable us to contribute to your development on either a risk-sharing or out-licensing basis. In order to consolidate a long term relationship with its partners, Delphi Genetics is currently developing a brand new GMP production facility. This mid-scale capacity facility will join technology and flexibility to provide plasmid DNA and protein with high value for your clinical phases.
Demander un devisVous vendez ou fabriquez des produits similaires ?
Inscrivez-vous sur europages et référencez vos produits
Résultats pour
Al technology - Import exportNombre de résultats
6 ProduitsType d'entreprise